Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CEL-SCI Corp - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
CVM
American
2836
https://cel-sci.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CEL-SCI Corp
CVM: Parallel Engagement on Four Fronts
- Apr 15th, 2024 10:36 am
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
- Mar 19th, 2024 1:00 pm
CEL-SCI Corporation Issues Letter to Shareholders
- Mar 6th, 2024 1:45 pm
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
- Feb 15th, 2024 1:00 pm
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
- Feb 13th, 2024 5:00 pm
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
- Feb 9th, 2024 1:30 pm
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
- Feb 6th, 2024 2:00 pm
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
- Jan 31st, 2024 2:00 pm
CVM: Fiscal Year 2023 in Review
- Jan 8th, 2024 9:32 am
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
- Dec 22nd, 2023 1:00 pm
CVM: NICE To Have Your Support
- Dec 8th, 2023 8:15 am
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
- Dec 4th, 2023 1:30 pm
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
- Nov 20th, 2023 9:15 pm
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
- Nov 16th, 2023 1:30 pm
12 Best Day Trading Stocks To Buy
- Nov 9th, 2023 1:52 pm
CVM: Target Population Comes Into Relief
- Nov 8th, 2023 10:06 am
CEL-SCI Issues Letter to Shareholders
- Oct 30th, 2023 1:20 pm
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
- Oct 24th, 2023 12:00 pm
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
- Oct 23rd, 2023 1:15 pm
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
- Oct 19th, 2023 12:00 pm
Scroll